Validation of the integrated 40-gene expression profile (i40-GEP) which provides prognostic and adjuvant radiation benefit for high-risk cutaneous squamous cell carcinoma
Journal of the American Academy of Dermatology · 2026-08
DOI: 10.1016/j.jaad.2026.08.075 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2026-08. Verfasst von Désirée Ratner und 10 weiteren Autor:innen. Beteiligte Einrichtung: Désirée Ratner, MD PC, New York, New York; Department of Dermatology, NYU Grossman School of Medicine, New York, New York. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Castle Biosciences Inc.
Abstract (Originalsprache)
BACKGROUND: Risk assessment in high-risk cutaneous squamous cell carcinoma uses several clinicopathologic staging system tools, yet under- and overtreatment often occur. Integration of tumor biology as an independent predictor via gene expression profile (GEP) may improve risk stratification and tailor adjuvant care. OBJECTIVE: Integrate clinicopathologic risk factors with 40-GEP testing to refine risk stratification. METHODS: Integrated 40-GEP (i40-GEP) combines optimized nested predictive models and 5 clinicopathologic features (immunosuppression, location, differentiation, tumor diameter, and perineural invasion) with the validated 40-GEP, and reports results: Class 1A (low risk), Class 1B (moderate risk), Class 2A (high risk), and Class 2B (highest risk). RESULTS: i40-GEP significantly stratifies metastatic and local recurrence risk (P 95% negative predictive value for Class 1A across National Comprehensive Cancer Network subsets. The i40-GEP identified 12.9% of patients as Class 2B, with the lowest 3-year metastasis-free survival (66.2%) and a demonstrated benefit from adjuvant radiation treatment (ART). Multivariable analysis showed i40-GEP results significantly predict metastatic and local recurrence risk more than individual clinicopathologic factors. LIMITATIONS: Retrospective study. CONCLUSIONS: i40-GEP accurately stratifies metastatic and local recurrence risk in patients with high-risk cutaneous squamous cell carcinoma, leading to improved clinical decision-making. Class 2B i40-GEP identifies patients most likely to benefit from ART.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Désirée Ratner, MD PC, New York, New York; Department of Dermatology, NYU Grossman School of Medicine, New York, New York.
- City of Hope Cancer Center, Chicago, Illinois.
- The Woodruff Institute, Naples, Florida.
- Harrison Dermatology & Research Group, Missouri City, Texas; University of Houston College of Medicine, Houston, Texas; Department of Dermatology, Baylor College of Medicine, Houston, Texas.
- Baylor Scott & White Health System, Dallas, Texas; Bare Dermatology, Dallas, Texas.
- Department of Dermatology, Indiana University School of Medicine, Orland Park, Illinois; SkinMD, LLC, Orland Park, Illinois.
Förderung
- Castle Biosciences Inc
Zitieren
APA
Ratner, D., Singh, G., Rizzo, J. M., Nguyen, H., Farberg, A. S., Somani, A. K., Siegel, J. J., Goldberg, M. S., Stebbins, W., Tolkachjov, S. N., & Arron, S. T. (2026). Validation of the integrated 40-gene expression profile (i40-GEP) which provides prognostic and adjuvant radiation benefit for high-risk cutaneous squamous cell carcinoma. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2026.08.075
Vancouver
Ratner D, Singh G, Rizzo JM, Nguyen H, Farberg AS, Somani AK, et al. Validation of the integrated 40-gene expression profile (i40-GEP) which provides prognostic and adjuvant radiation benefit for high-risk cutaneous squamous cell carcinoma. Journal of the American Academy of Dermatology. 2026. doi:10.1016/j.jaad.2026.08.075
BibTeX
@article{Ratner2026,
author = {Ratner, Désirée and Singh, Gaurav and Rizzo, Jason M and Nguyen, Harrison and Farberg, Aaron S and Somani, Ally-Khan and Siegel, Jennifer J and Goldberg, Matthew S and Stebbins, William and Tolkachjov, Stanislav N and Arron, Sarah T},
title = {Validation of the integrated 40-gene expression profile (i40-GEP) which provides prognostic and adjuvant radiation benefit for high-risk cutaneous squamous cell carcinoma},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
doi = {10.1016/j.jaad.2026.08.075}
}
EUVIMED